Evidence mapPaperPMID 40214899Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2025

The Urgent Need for Breakthrough Therapies and a World Without Type 1 Diabetes.

Lynn Starr, Sanjoy Dutta, Thomas Danne, Stephen R Karpen, Campbell Hutton, Aaron Kowalski

Abstract read
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trajectory of Kidney Function in T1D over Time: A Scoping Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lynn StarrBreakthrough T1D, 1400 K St. NW Suite 1200, Washington, DC, 20005, USA.
Sanjoy DuttaBreakthrough T1D, 200 Vesey Street, 28th Floor, New York, NY, 10281, USA.ORCID http://orcid.org/0000-0001-8117-1677
Thomas DanneBreakthrough T1D, 200 Vesey Street, 28th Floor, New York, NY, 10281, USA.ORCID http://orcid.org/0000-0002-8424-3944
Stephen R KarpenBreakthrough T1D, 1400 K St. NW Suite 1200, Washington, DC, 20005, USA. skarpen@BreakthroughT1D.org.ORCID http://orcid.org/0000-0002-9063-8010
Campbell HuttonBreakthrough T1D, 1400 K St. NW Suite 1200, Washington, DC, 20005, USA.ORCID http://orcid.org/0000-0002-3897-3882
Aaron KowalskiBreakthrough T1D, 200 Vesey Street, 28th Floor, New York, NY, 10281, USA.ORCID http://orcid.org/0000-0002-0979-5343

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite significant progress, type 1 diabetes (T1D) still results in premature death, significant complications, and a substantial daily burden for those affected. T1D remains a lifelong condition that demands constant vigilance and resilience and has a significant social and economic impact. Individuals with T1D must walk a tightrope to minimize disease-related complications that result from insufficient insulin while also avoiding adverse effects from too much insulin. Achieving this balance is challenging, as diet, activity, medications, physiology, the environment, stress, and many other aspects of daily living all affect glucose levels, often differently from day to day. Persistent challenges of T1D go beyond maintaining glycemic control and include managing long-term complications and preventing potentially life-threating adverse reactions from insulin therapy, and the emotional and cognitive burdens that often lead to diabetes distress and burnout. The T1D community-researchers, sponsors, clinicians, those living with T1D, and advocates-must look beyond managing symptoms of T1D and aim for better treatments and to bring cures. Emerging therapies need clear and efficient regulatory pathways, and new solutions are needed to address ongoing regulatory challenges. The perspectives of people with T1D must be front and center in research and regulatory decision-making. Through the collective efforts of the T1D community, the urgent needs of those with T1D can be met, and T1D can be made a thing of the past.

Indexed as

Diabetes burnoutDiabetes distressDrug developmentGlycemic managementHypoglycemiaRegulatoryT1DType 1 diabetesUnmet needs

Identifiers

PMID40214899
PMCPMC12085400

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.